P-Glycoprotein, a gatekeeper in the blood-brain barrier

Advanced Drug Delivery Reviews

Volumn 36, Issue 2-3, 1999, Pages 179-194

  Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Brain capillary endothelial cells; Drug transport; Knockout mice; Multidrug resistance genes; Neurotoxicity; P Glycoprotein blockers; Pharmacokinetics

Indexed keywords

BLOOD; BRAIN; CELLS; GENES; NEUROPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; PROTEINS;

BLOOD-BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELLS; MULTIDRUG RESISTANCE GENES; NEUROTOXICITY; P-GLYCOPROTEIN;

CONTROLLED DRUG DELIVERY;

CYCLOSPORIN A; DEXAMETHASONE; DIGOXIN; DOMPERIDONE; DOXORUBICIN; ERYTHROMYCIN; GLYCOPROTEIN P; INDINAVIR; IVERMECTIN; LOPERAMIDE; NELFINAVIR; ONDANSETRON; PACLITAXEL; SAQUINAVIR; VINBLASTINE;

ANIMAL EXPERIMENT; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ENDOTHELIUM CELL; HUMAN; KNOCKOUT MOUSE; MOUSE; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0033526176     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00085-4     Document Type: Review

References (79)

1. M. Naito, T. Tsuruo, Role of P-glycoprotein in the blood-brain barrier. In: S. Gupta, T. Tsuruo (Eds.), Multidrug Resistance in Cancer Cells, John Wiley and Sons, Ltd., Chichester, 1996, pp. 321-333.
2. Tsuji A., Tamai I. Blood-brain barrier function of P-glycoprotein. Adv. Drug Deliv. Rev. 25:1997;287-298.
3. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
4. Roninson I.B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem. Pharmacol. 43:1992;95-102.
5. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
6. Ruetz S., Gros P. A mechanism for P-glycoprotein action in multidrug resistance: are we there yet? Trends Pharmacol. Sci. 15:1994;260-263.
7. Borst P., Schinkel A.H. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet. 13:1997;217-222.
8. Pan B.-F., Dutt A., Nelson J.A. Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. J. Pharmacol. Exp. Ther. 270:1994;1-7.
9. Van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 87:1996;507-517.
10. De Graaf D., Sharma R.K., Mechetner E.B., Schimke R.T., Roninson I.B. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc. Natl. Acad. Sci. USA. 93:1996;1238-1242.
11. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:1992;18-21.
12. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1981;1967-1972.
13. Fisher G.A., Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 9:1995;363-382.
14. Goldstein L. Clinical reversal of drug resistance. Curr. Probl. Cancer. XIX:1995;67-124.
15. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:1993;4595-4602.
16. Witherspoon S.M., Emerson D.L., Kerr B.M., Lloyd T.L., Dalton W.S., Wissel P.S. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin. Cancer Res. 2:1996;7-12.
17. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., Starling J.J. Reversal of P-glycoprotein-mediated resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56:1996;4171-4179.
18. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:1987;7735-7738.
19. Croop J.M., Raymond M., Haber D., Devault A., Arceci R.J., Gros P., Housman D.E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol. Cell. Biol. 9:1989;1346-1350.
20. Arceci R.J., Croop J.M., Horwitz S.B., Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc. Natl. Acad. Sci. USA. 85:1988;4350-4354.
21. Hsu S.I.-H., Lothstein L., Horwitz S.B. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J. Biol. Chem. 264:1989;12053-12062.
22. Devault A., Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol. 10:1990;1652-1663.
23. Schinkel A.H., Smit J.J.M., Van Tellingen O., Beijnen J.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Van der Valk M.A., Robanus-Maandag E.C., Te Riele H.P.J., Berns A.J.M., Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
24. Schinkel A.H., Mayer U., Wagenaar E., Mol C.A.A.M., Van Deemter L., Smit J.J.M., Van der Valk M.A., Voordouw A.C., Spits H., Van Tellingen O., Zijlmans J.M.J.M., Fibbe W.E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA. 94:1997;4028-4033.
25. Sparreboom A., Van Asperen J., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K.F., Borst P., Nooijen W.J., Beijnen J.H., Van Tellingen O. Limited oral bio-availability and active epithelial excretion of paclitaxel (taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:1997;2031-2035.
26. Van Asperen J., van Tellingen O., Sparreboom A., Schinkel A.H., Borst P., Nooijen W.J., Beijnen J.H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer. 76:1997;1181-1183.
27. Van Asperen J., Schinkel A.H., Beijnen J.H., Nooijen W.J., Borst P., Van Tellingen O. Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein deficient mice. J. Natl. Cancer Inst. 88:1996;994-999.
28. Mayer U., Wagenaar E., Beijnen J.H., Smit J.W., Meijer D.K.F., Van Asperen J., Borst P., Schinkel A.H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br. J. Pharmacol. 119:1996;1038-1044.
29. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:1997;2430-2436.
30. Smit J.W., Schinkel A.H., Mhller M., Weert B., Meijer D.K.F. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with a mdr1a gene disruption. Hepatology. 27:1998;1056-1063.
31. Goldstein G.W., Betz A.L. The blood-brain barrier. Sci. Am. 255:1986;70-79.
32. Pardridge W.M. Recent advances in blood-brain barrier transport. Ann. Rev. Pharmacol. Toxicol. 28:1988;25-39.
33. Bradbury M.W.B. The blood-brain barrier. Exp. Phys. 78:1993;453-472.
34. Bradbury M.W.B. The blood-brain barrier. Circulation Res. 57:1985;213-222.
35. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:1980;682-684.
36. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:1989;695-698.
37. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37:1989;159-164.
38. Van der Valk P., van Kalken C.K., Ketelaars H., Broxterman H.J., Scheffer G., Kuiper C.M., Tsuruo T., Lankelma J., Meijer C.J.L.M., Pinedo H.M., Scheper R.J. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann. Oncol. 1:1990;56-64.
39. Sugawara I., Hamada H., Tsuruo T., Mori S. Specialized localization of P-glycoprotein recognized by MRK16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn. J. Cancer Res. 81:1990;727-730.
40. Tanaka Y., Abe Y., Tsugu A., Takamiya Y., Akatsuka A., Tsuruo T., Yamazaki H., Ueyama Y., Sato O., Tamaoki N., Nakamura M. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch. 425:1994;133-138.
41. Tóth K., Vaughan M.M., Peress N.S., Slocum H.K., Rustum Y.M. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am. J. Pathol. 149:1996;853-858.
42. J.B.M.M. Van Bree, A.G. de Boer, M. Danhof, D.D. Breimer, Drug transport across the blood-brain barrier. In: J.B.M.M. van Bree (Ed.), Drug Transport Across the Blood-Brain Barrier, PhD Thesis, University of Leiden, All In BV, Katwijk, 1990, pp. 8-62.
43. Sugawara I. Expression and functions of P-glycoprotein (mdr1 gene product) in normal and malignant tissues. Acta Pathol. Jpn. 40:1990;545-553.
44. Tsuji A., Terasaki T., Takabatake Y., Tenda Y., Tamai I., Yamashima T., Moritani S., Tsuruo T., Yamashita J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1992;1427-1437.
45. Stewart P.A., Béliveau R., Rogers K.A. Cellular localization of P-glycoprotein in brain versus gonadal capillaries. J. Histochem. Cytochem. 44:1996;679-685.
46. Jetté L., Murphy G.F., Leclerc J., Béliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem. Pharmacol. 50:1995;1701-1709.
47. Cumber P.M., Jacobs A., Hoy T., Fisher J., Whittaker J.A., Tsuruo T., Padua R.A. Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. Br. J. Haematol. 76:1990;226-230.
48. J.P. O'Brien, C. Cordon-Cardo, P-glycoprotein expression in normal human tissues. In: S. Gupta, T. Tsuruo (Eds.), Multidrug Resistance in Cancer Cells, John Wiley and Sons, Ltd., Chichester, 1996, pp. 285-291.
49. Finstad C.L., Yin B.W.T., Gordon C.M., Federici M.G., Welt S., Lloyd K.O. Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis. J. Histochem. Cytochem. 39:1991;1603-1610.
50. Beaulieu E., Demeule M., Ghitescu L., BJliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 326:1997;539-544.
51. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 36:1995;1-6.
52. Pardridge W.M., Golden P.L., Kang Y.-S., Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 68:1997;1278-1285.
53. Tatsuta T., Naito M., Oh-hara T., Sugawara I., Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267:1992;20383-20391.
54. Tsuji A., Tamai I., Sakata A., Tenda Y., Terasaki T. Restricted transport of cyclosporin A across the blood-brain by a multidrug transporter. P-glycoprotein. Biochem. Pharmacol. 146:1993;1096-1099.
55. Hegmann E.J., Bauer H.C., Kerbel R.S. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 52:1992;6969-6975.
56. Jetté L., Pouliot J., Murphy G.F., Béliveau R. Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Evidence for cross-reactivity of antibody C219 with an unrelated protein. Biochem. J. 305:1995;761-766.
57. Barrand M.A., Robertson K.J., Von Weikersthal S.F. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett. 374:1995;179-183.
58. Biegel D., Spencer D.D., Pachter J.S. Isolation and culture of human brain microvessel endothelial cells for the study of blood-brain barrier properties in vitro. Brain Res. 692:1995;183-189.
59. Shirai A., Naito M., Tatsuta T., Dong J., Hanaoka K., Mikami K., Oh-hara T., Tsuruo T. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. Biophys. Acta. 1222:1994;400-404.
60. Schinkel A.H., Wagenaar E., Van Deemter L., Mol C.A.A.M., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
61. Lankas G.R., Cartwright M.E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143:1997;357-365.
62. Umbenhauer D.R., Lankas G.R., Pippert T.R., Wise L.D., Cartwright M.E., Hall S.J., Beare C.M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:1997;88-94.
63. Pulliam J.D., Seward R.L., Henry R.T., Steinberg S.A. Investigating ivermectin hypersensitivity in collies. Vet. Med. 80:1985;33-40.
64. Schinkel A.H., Wagenaar E., Mol C.A.A.M., Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
65. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
66. Lee C.G.L., Gottesman M.M. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J. Clin. Invest. 101:1998;287-288.
67. Arboix M., Gonzalez Paz O., Colombo T., D'Incalci M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther. 281:1997;1226-1230.
68. Sakata A., Tamai I., Kawazu K., Deguchi Y., Ohnishi T., Saheki A., Tsuji A. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48:1994;1989-1992.
69. Wang Q., Yang H., Miller D.W., Elmquist W.F. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem. Biophys. Res. Comm. 211:1995;719-726.
70. Chikhale E.G., Burton P.S., Borchardt R.T. The effect of verapamil on the transport of peptides across the blood brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J. Pharmacol. Exp. Ther. 273:1995;298-303.
71. Lemaire M., Bruelisauer A., Guntz P., Sato H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother. Pharmacol. 38:1996;481-486.
72. Drion N., Lemaire M., Lefauconnier J.-M., Scherrmann J.-M. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J. Neurochem. 67:1996;1688-1693.
73. Desrayaud S., Guntz P., Scherrmann J.-M., Lemaire M. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. 61:1997;153-163.
74. Drion N., Risede P., Cholet N., Chanez C., Scherrmann J.M. Role of P-170 P-glycoprotein in colchicine brain uptake. J. Neurosci. Res. 49:1997;80-88.
75. Didier A.D., Loor F. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int. J. Cancer. 63:1995;263-267.
76. Seelig A., Gottschlich R., Devant R.M. A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 91:1994;68-72.
77. Ecker G., Chiba P. Structure-activity relationship studies on modulators of the multidrug transporter P-glycoportein-an overview. Wien. Klin. Wochenschr. 107:1995;681-686.
78. Van Asperen J., Mayer U., van Tellingen O., Beijnen J.H. The functional role of P-glycoprotein in the blood-brain barrier. J. Pharm. Sci. 86:1997;881-884.
79. Schuetz E.G., Yasuda K., Arimori K., Schuetz J.D. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not retinoic acid or benzo(a)pyrene. Arch. Biochem. Biophys. 350:1998;340-347.